Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UK3A
|
|||
| Drug Name |
Hydroxychloroquine
|
|||
| Synonyms |
Hidroxicloroquina; Hidroxicloroquina [INN-Spanish]; Hydroxychlorochin; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hydroxychloroguine; Hydroxychloroquine (INN);Hydroxychloroquine [INN:BAN]; Hydroxychloroquine Sulfate (1:1) Salt; Hydroxychloroquinum; Hydroxychloroquinum [INN-Latin]; Idrossiclorochina; Idrossiclorochina [DCIT]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Plaquenil (TN); Polirreumin; Polirreumin (TN); Quensyl; WIN 1258
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Malaria [ICD-11: 1F40-1F45; ICD-9: 84] | Approved | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 3 | [2], [3] | ||
| Comment |
Hydroxychloroquine is being studied in clinical trials for COVID-19, and FDA authorized its temporary use during the COVID-19 pandemic under limited circumstances through the EUA, and not through regular FDA approval.
|
|||
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
Concordia Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H26ClN3O
|
|||
| Canonical SMILES |
CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO
|
|||
| InChI |
1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
|
|||
| InChIKey |
XXSMGPRMXLTPCZ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 118-42-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9255, 597669, 3140459, 5137975, 7979547, 8150104, 8152307, 10505161, 11336117, 11361356, 11462328, 11484852, 11489054, 14777730, 29215442, 29222777, 46508459, 47662363, 47885484, 48416094, 49967663, 57321921, 75004190, 85286187, 96024743, 99302030, 103566848, 104304133, 118262645, 124573764, 126687853, 129756062, 134338155, 134973873, 135702786, 136890426, 137083308, 143201344, 143401603, 160964848, 162180925, 163835395, 163836798, 165716210, 172829147, 174006176, 175607648, 177748295, 178103773, 179039315
|
|||
| ChEBI ID |
CHEBI:5801
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN glycosylation of host receptor (GHR) | Target Info | Inhibitor | [4], [5] |
| HUMAN pH-dependent viral fusion/replication (pH-DVF/R) | Target Info | Inhibitor | [4], [5] | |
| HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway) | Target Info | Inhibitor | [6], [7] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | ClinicalTrials.gov (NCT04341727) Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection (WU352). U.S. National Institutes of Health. | |||
| REF 3 | Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ 2020. April. 01; 369:m1335 | |||
| REF 4 | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. | |||
| REF 5 | Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol. 2020 Apr;15(4):247-249. | |||
| REF 6 | Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. | |||
| REF 7 | Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Ann Intern Med. 2020 Mar 31. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.